Evidence map›Paper›PMID 34805556›Full record

ArticleBMJ paediatrics open2021

Multicentre service evaluation of presentation of newly diagnosed cancers and type 1 diabetes in children in the UK during the COVID-19 pandemic.

Gemma Williams, Ross McLean, Jo-Fen Liu, Timothy A Ritzmann, Madhumita Dandapani, Dhurgshaarna Shanmugavadivel, Pooja Sachdev, Mark Brougham, Rod T Mitchell, Nicholas T Conway and 6 more

Abstract readMulticenter Study
In one paragraph

Article in BMJ paediatrics open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Gemma WilliamsPaediatric Oncology, Leeds Children's Hospital, Leeds, UK.
Ross McLeanDepartment of Paediatrics, University Hospital Wishaw, Wishaw, UK.
Jo-Fen LiuChildren's Brain Tumour Research Centre, University of Nottingham, Nottingham, UK.
Timothy A RitzmannChildren's Brain Tumour Research Centre, University of Nottingham, Nottingham, UK.
Madhumita DandapaniChildren's Brain Tumour Research Centre, University of Nottingham, Nottingham, UK.
Dhurgshaarna ShanmugavadivelChildren's Brain Tumour Research Centre, University of Nottingham, Nottingham, UK.
Pooja SachdevDepartment of Paediatric Diabetes and Endocrinology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Mark BroughamDepartment of Paediatric Oncology, Royal Hospital for Children and Young People, Edinburgh, UK.
Rod T MitchellMRC Centre for Reproductive Health, The University of Edinburgh, Edinburgh, UK.
Nicholas T ConwayDepartment of Paediatrics, Tayside Children's Hospital, Dundee, UK.
James LawDepartment of Paediatric Diabetes and Endocrinology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Alice CunningtonDivision of Family Health, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Gbemi OgunnaikeDepartment of Paediatric Diabetes and Endocrinology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Karen BroughamDepartment of Paediatric Oncology, Royal Hospital for Children and Young People, Edinburgh, UK.
Elizabeth BaymanDepartment of Paediatric Diabetes and Endocrinology, Royal Hospital for Sick Children, Edinburgh, UK.
David WalkerChildren's Brain Tumour Research Centre, University of Nottingham, Nottingham, UK.ORCID 0000-0002-1753-0839

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The COVID-19 pandemic led to changes in patterns of presentation to emergency departments. Child health professionals were concerned that this could contribute to the delayed diagnosis of life-threatening conditions, including childhood cancer (CC) and type 1 diabetes (T1DM). Our multicentre, UK-based service evaluation assessed diagnostic intervals and disease severity for these conditions. Methods: We collected presentation route, timing and disease severity for children with newly diagnosed CC in three principal treatment centres and T1DM in four centres between 1 January and 31 July 2020 and the corresponding period in 2019. Total diagnostic interval (TDI), patient interval (PI), system interval (SI) and disease severity across different time periods were compared. Results: For CCs and T1DM, the route to diagnosis and severity of illness at presentation were unchanged across all time periods. Diagnostic intervals for CCs during lockdown were comparable to that in 2019 (TDI 4.6, PI 1.1 and SI 2.1 weeks), except for an increased PI in January-March 2020 (median 2.7 weeks). Diagnostic intervals for T1DM during lockdown were similar to that in 2019 (TDI 16 vs 15 and PI 14 vs 14 days), except for an increased PI in January-March 2020 (median 21 days). Conclusions: There is no evidence of diagnostic delay or increased illness severity for CC or T1DM, during the first phase of the pandemic across the participating centres. This provides reassuring data for children and families with these life-changing conditions.

Indexed as

COVID-19Diabetes Mellitus, Type 1NeoplasmsChildCommunicable Disease ControlDelayed DiagnosisHumansPandemicsSARS-CoV-2United KingdomCOVID-19

Identifiers

PMID34805556
PMCPMC8587587

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.